跳至主要内容
临床试验/NL-OMON45353
NL-OMON45353尚未招募不适用

SAFETY AND PERFORMANCE OF THE TRIALIGN PERCUTANEOUS TRICUSPID VALVE ANNULOPLASTY SYSTEM (PTVAS) FOR SYMPTOMATIC CHRONIC FUNCTIONAL TRICUSPID REGURGITATION - SCOUT-II

Mitralign Inc.0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. >=18 and <=85 years old
  • 2. New York Heart Association (NYHA) Class II, III or ambulatory IV
  • 3. Symptomatic despite Guideline Directed Medical Therapy (GDMT) for at least 1 month; including diuretics
  • 4. The patient is at high risk for open heart valve surgery
  • 5. The heart team recommends tricuspid annuloplasty, in accordance with the recommendations of the 2012 ESC Valve Guidelines
  • 6. Patient or legal guardian understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
  • 7. Patient is willing and able to comply with all specified study evaluations

排除标准

  • 1. History of heart transplant
  • 2. Severe uncontrolled hypertension (SBP >= 180 mmHg and/or DBP >= 110 mmHg)
  • 3. Previous tricuspid valve repair or replacement (including artificial valve)
  • 4. Presence of LVAD, trans-tricuspid pacemaker or defibrillator leads
  • 5. Active endocarditis
  • 6. Severe coronary artery disease

研究者

相似试验